Accessibility Menu
Algernon Health logo

Algernon Health(OTC) AGNPF

Market Cap$1.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-98%
1 Year-25%
1 Month+1%
$0.30
+0%
+0.00Today
Algernon Health last closing stock price
MetricPriceDate
Last closeUSD 0.302026-07-29
Algernon Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.24%USD 0.292026-07-22
1 month+1.11%USD 0.302026-06-29
3 month-3.91%USD 0.312026-04-30
Year to date-40.04%USD 0.502025-12-31
1 year-25.05%USD 0.402025-07-29
3 year-81.26%USD 1.602023-07-28
5 year-98.29%USD 17.502021-07-30
Since inception-99.79%USD 145.282016-03-11

Algernon Health Financials at a Glance

Market Cap

$1.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$2.34M

EPS (TTM)

-$0.42

P/E Ratio

-0.71

Dividend

$0.00

Beta (Volatility)

0.08 (Low)

Price

$0.30

Volume

12

Open

$0.29

Previous Close

$0.30

Daily Range

$0.29 - $0.30

52-Week Range

$0.23 - $0.64

Estimated Earnings Date

Jul 29, 2026

AGNPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Algernon Health

Algernon Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing innovative therapies for various challenging medical conditions. The company is engaged in clinical trials for treatments targeting non-alcoholic steatohepatitis, chronic kidney disease, and other serious health issues, primarily operating in Canada and Australia.

Products and Services
  • Investigational drug NP-120 for multiple medical conditions
  • AP-188, a psychedelic agent for ischemic stroke treatment
  • Collaboration with Charles River Laboratories for preclinical research
Growth Outlook
  • Strong pipeline addressing unmet medical needs in various diseases
  • Partnerships enhancing research capabilities and market reach
  • Focus on innovative therapies positions the company for future growth
Financial Highlights
  • Recent quarterly net income of -$499,476, reflecting ongoing investment in R&D
  • Cash and short-term investments of $195,330 as of February 2026
  • Operating expenses of $464,296 in the latest quarter, indicating active development
Algernon Pharmaceuticals Inc. is positioned in the biotechnology sector, focusing on the development of drugs that address significant health challenges. The company's flagship product, NP-120, is designed to target specific receptors involved in various diseases, while AP-188 represents a novel approach to treating ischemic stroke. The collaboration with Charles River Laboratories enhances the company's research capabilities, potentially accelerating the development of its therapies. Financially, the company is in a phase of heavy investment, as indicated by the recent net income loss and substantial operating expenses. However, the cash reserves provide a foundation for continued research and development efforts. The strategic focus on innovative therapies and partnerships may offer significant growth opportunities in the evolving biopharmaceutical landscape.
AI Generated • Jul 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Chris Moreau

Website

www.algernonpharmaceuticals.com

Headquarters

Vancouver, BC V5Z 4C2, CA

AGNPF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-106.60%

Return on Capital

-63.74%

Return on Assets

N/A

Earnings Yield

-1.41%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.42M

Volume

12

Avg. Volume

11.81K

Financials (TTM)

Gross Profit

-CA$104.15K

Operating Income

-CA$2.06M

EBITDA

-CA$1.49M

Operating Cash Flow

-CA$1.49M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$1.49M

Cash & ST Invst.

CA$195.33K

Total Debt

CA$0.00

Algernon Health Performance Analysis

Algernon Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 0N/A
20232023-08-31CAD 0N/A
20242024-08-31CAD 0N/A
20252025-08-31CAD 0N/A
Algernon Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-31N/A
Q42025-08-31N/A
Q12025-11-30N/A
Q22026-02-28N/A
Algernon Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD -5.74-30.0%
20232023-08-31CAD -3.32-42.0%
20242024-08-31CAD -0.18-94.5%
20252025-08-31CAD -0.42126.2%
Algernon Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-31-38.9%
Q42025-08-3144.5%
Q12025-11-30-53.2%
Q22026-02-2835.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$35.28K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$324.88K

N/A

Employees

5

N/A

Net Income

-CA$499.48K

-34.2%

EBITDA

-CA$464.30K

-26.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$195.33K

+111.9%

Total Debt

CA$0.00

N/A

Accounts Receivable

CA$26.65K

+36.3%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-CA$465.94K

-86.8%

Operating Cash Flow

-CA$465.94K

-86.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APLIFAppili Therapeutics Inc
$0.01+0.00%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
AAGHAmerica Great Health
$0.00+0.00%
VGLSSB Technology Holdings Inc.
$0.22+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About AGNPF

What is the current price of Algernon Health?

Algernon Health is trading at $0.30 per share.

What is the 52-week range for Algernon Health?

Over the past 52 weeks, Algernon Health has traded between $0.23 and $0.64.

How much debt does Algernon Health have?

As of the most recent reporting period, Algernon Health reported total debt of CA$0.00.

How much cash does Algernon Health have on hand?

Algernon Health reported CA$143.23K in cash and cash equivalents in its most recent financial results.

What is Algernon Health’s dividend yield?

Algernon Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services